

FIG.1




FIG.2





FIG.3

**4M45**



**FIG. 4**

20170306 09:00




FIG.5A




FIG.5B




FIG.5C




FIG.5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G




FIG. 6H






FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8





FIG. 9




**FIG.10**

Figure 1 is a line graph showing the CSF Anti-MBP level (Ru) over time for two groups of mice, it #1 and it #2. The y-axis represents the CSF Anti-MBP level (Ru) from 0 to 15. The x-axis represents time points: 0, 1h, and 24h for both groups. Group it #1 (solid line, filled circles) shows a high level at 0 (approx. 15.5) and low levels at 1h and 24h (approx. 1.2 and 0.8). Group it #2 (dashed line, open circles) shows low levels at 0 (approx. 1.8) and 24h (approx. 1.5), with a peak at 1h (approx. 5.8). Shaded vertical bars indicate the time intervals for MBP administration: B1 (0-1h), 1d1 (1-24h), 1w1 (1-24h), and 4w1 (0-24h).

Group	Time Point	CSF Anti-MBP level (Ru)
it #1	0	15.5
	1h	1.2
	24h	0.8
it #2	0	1.8
	1h	5.8
	24h	1.5

FIG. 11a

20170304000000






FIG. 11c



207710-69467860




FIG. 11d

FIG. 12



MBP 82-98:  
500 mg IV #3

CONFIDENTIAL




FIG.15

Figure 16 is a line graph showing CSF Anti-MBP level (Ru) on the y-axis (ranging from 0 to 15) against time on the x-axis. The top x-axis shows dates from Jan.85 to Dec.95. The bottom x-axis shows time points from Pre B1 to 6w2. The graph includes several data series: IV #1(B1), it #3(B1), it #4, it #5, it #6, and it #2. Shaded bars indicate MBP treatment periods. The graph shows a significant decrease in CSF Anti-MBP level (Ru) following MBP treatment, with a subsequent recovery phase.

FIG. 16




FIG. 17A




FIG. 17B



**FIG. 18**